Physician profile
Vivek Kumar
NPI 1336671288
$2,031.84
in general payments reported to CMS, 2019-2025
16 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.30 · 2022: $605 · 2023: $634 · 2024: $567 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.53 | 2022-2024 | |
| Oyster Point Pharma, INC. | $220.10 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $166.77 | 2024-2025 | Vevye |
| Rxsight INC | $130.96 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Glaukos Corporation | $125.73 | 2022 | |
| Bausch & Lomb Americas INC. | $125.00 | 2022 | |
| Allergan, INC. | $108.73 | 2021-2022 | |
| Alcon Vision LLC | $92.08 | 2023-2025 | Simbrinza |
| Biotissue Holdings INC. | $68.60 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $60.92 | 2023-2025 | Cequa |
| Amgen INC. | $52.57 | 2024 | Tepezza |
| Beaver-Visitec International, INC. | $46.07 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $38.20 | 2024 | Xdemvy |
| Dompe US, INC. | $28.66 | 2023 | Oxervate |
| Genentech USA, INC. | $24.45 | 2024 | Vabysmo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $13.47 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.